Jan is a partner and member of SEP’s Investment Committee. She has an operational and commercial background in the pharmaceutical industry, and leads SEP’s healthcare investment activities, with a particular interest in digital health.

Jan led SEP’s investment in Exco InTouch, a leading provider of mobile patient communication and management solutions for clinical research and healthcare providers, which was sold to ERT; and was a member of the deal team responsible for SEP’s investment in BioVex, working closely with the company’s management team until its $1bn exit to Amgen. She was also a member of the deal team leading SEP’s investment in Dotmatics, a global scientific informatics software provider.

She has a BSc (Hons) in Pharmacy from Robert Gordon University and an MBA from Henley Business School.

Outside of SEP, Jan is a Trustee of the National Deaf Children’s Society.

‍